SGLT2 Inhibitor Adds Years of Life to Patients With Heart Failure

“Patients with heart failure with reduced ejection fraction (HFrEF) may increase their lifespan if they take the SGLT2 inhibitor dapagliflozin (Farxiga) over the long term, a statistical modeling study showed.

Mean event-free survival was an estimated 8.3 years in a patient with HFrEF who started dapagliflozin at age 65. As a similar patient on standard therapy alone would only be expected to live free from heart failure events for another 6.2 years, this represented an event-free survival time gain of 2.1 years (P=0.002).”

Learn more, here.